Product Information

DABIGATRAN ETEXILATE 150 MG CP is a generic product labeled by Mylan Pharmaceuticals Inc., priced at $0.8226 per EA under NDC 00378026691. Its NADAC has been published 73 times since Apr 2, 2025.

FDA first approved this application on Feb 3, 2025. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.

The Low Outlier badge above means this manufacturer's average price in the Dabigatran Etexilate market falls below Q1 − 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.

Price Statistics

The NADAC for DABIGATRAN ETEXILATE 150 MG CP has been published 73 times since Apr 2, 2025, and over the history we have for it it has declined 50.1%. The table below summarizes its recorded NADAC range and movement.

Generic Alternatives

The matcher finds 4 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.